+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
FEMALE
ID06840002

Open Multicenter Study of SHR-A1811 Combined With Chemotherapy for Treating Platinum Sensitive Recurrent Ovarian Cancer

Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-09-11

150

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of SHR-A1811 with carboplatin and bevacizumab in treating platinum sensitive recurrent epithelial ovarian cancer. The study aims to assess how well patients tolerate this combination, its safety, how the body processes the drugs, immune response triggered, and to determine the recommended dose for phase II. It also preliminarily evaluates the treatments effectiveness in this patient group. Participants receive SHR-A1811 combined with chemotherapy drugs including carboplatin and bevacizumab. The treatment is administered under medical supervision in a single group setting. The study is conducted in two phases, phase Ib and II, focusing on finding the right dose and monitoring treatment outcomes over time. Participants will be closely monitored through regular assessments including measuring tumor response every 9 weeks for about a year. Safety is tracked from the first dose until 90 days after the last dose. Researchers will also observe overall survival for up to three years after enrollment ends. Tests include evaluating toxicity, response rates, disease control, progression-free survival, and adverse events throughout the study.

CONDITIONS

Brief Title

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Research Team

S

Shuni Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here